1
NURS 6521 ADVANCED PHARMACOLOGY NEURO &
MUSCULOSKELETAL DECISION TREE FULL PACKAGE QUESTIONS
ANSWERS AND RATIONALES 2026-27 LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
INTRODUCTION
The NURS 6521: Advanced Pharmacology examination evaluates graduate-level nursing candidates
on their mastery of advanced prescriptive logic, pharmacokinetics, and pharmacodynamics across
the lifespan. This specialized module focuses on the Neurological and Musculoskeletal Decision
Tree, assessing a clinician's ability to translate complex pathophysiological pathways into safe,
targeted drug therapy. Prescribing for neuro-musculoskeletal conditions requires a deep
understanding of neurotransmitter dynamics, drug-metabolizing enzyme pathways, blood-brain
barrier penetration variables, and national safety alerts like the Beers Criteria.
Advanced practice nurses must navigate challenging clinical situations, such as managing dopamine
agonist selection in Parkinson's disease, adjusting antiepileptic drug (AED) regimens based on hepatic
autoinduction, mitigating the toxicities of biologic response modifiers in rheumatoid arthritis, and
evaluating the safety profiles of muscle relaxants in older adults. This comprehensive question bank
provides scenario-based, application-level questions that mirror the construction of the actual exam.
By engaging with these high-fidelity items and their detailed rationales, candidates can eliminate
knowledge deficits and develop the diagnostic reasoning needed to pass the NURS 6521 examination
on their first attempt.
CORE DOMAINS TESTED
• Domain 1: Neurodegenerative Disorders & Dopaminergic Pathways – Prescriptive decision
trees for Parkinson's disease, Alzheimer's dementia, and corresponding drug-drug
interactions.
• Domain 2: Advanced Seizure Management & Antiepileptic Pharmacokinetics – AED
selection based on seizure classification, enzyme-inducing characteristics, and narrow
therapeutic index monitoring.
• Domain 3: Neuropathic Pain & Chronic Pain Pharmacotherapeutics – Clinical selection of
calcium channel alpha-2-delta ligands, SNRIs, and safety profiles for chronic neuropathic
states.
• Domain 4: Inflammatory and Autoimmune Musculoskeletal Disorders – Biological and non-
biological DMARD decision trees, uric acid mitigation strategies for gout, and glucocorticoid
titration hazards.
• Domain 5: Muscle Spasticity and Skeletal Muscle Relaxants – Differentiation between
centrally acting antispasmodics and peripherally acting muscle relaxants, highlighting
geriatric toxicities.
,2
Q1: A 67-year-old male with a 5-year history of Parkinson's disease
presents with worsening bradykinesia and rigid tremors. He has been
taking carbidopa-levodopa 25/100 mg three times daily. The nurse
practitioner notes that his symptoms return approximately 45
minutes before his next scheduled dose. Which of the following is the
most appropriate next pharmacotherapeutic step in this patient's
decision tree?
A) Discontinue carbidopa-levodopa and initiate high-dose
pramipexole monotherapy.
B) Add entacapone (Comtan) to the current carbidopa-levodopa
regimen.
C) Add benztropine (Cogentin) to manage the motor fluctuations.
D) Increase the carbidopa-levodopa dose and add immediate-release
diphenhydramine.
Rationale: The correct answer is B because the patient is experiencing
the classic "wearing-off" phenomenon associated with long-term
levodopa therapy. Entacapone is a selective, reversible catechol-O-
methyltransferase (COMT) inhibitor that extends the plasma half-life
of levodopa by blocking its peripheral metabolism, thereby increasing
its availability to the brain and mitigating wearing-off intervals.
Option A is incorrect because abruptly discontinuing carbidopa-
levodopa can precipitate neuroleptic malignant syndrome-like
withdrawal and pramipexole monotherapy is insufficient for
advanced disease. Option C is incorrect because benztropine is an
anticholinergic that poses severe central nervous system risks in an
older adult, including confusion and urinary retention under the Beers
Criteria. Option D is incorrect because adding diphenhydramine
increases the anticholinergic burden without addressing the specific
pharmacokinetic mechanism of levodopa clearance.
,3
Q2: A 28-year-old female patient with a new diagnosis of focal
impaired awareness seizures is being started on antiepileptic
monotherapy. She emphasizes that she uses an oral contraceptive pill
(OCP) for birth control and wants to avoid any interactions that could
result in unintended pregnancy. Which of the following antiepileptic
medications is the most appropriate choice for this patient?
A) Carbamazepine (Tegretol)
B) Phenytoin (Dilantin)
C) Topiramate (Topamax)
D) Levetiracetam (Keppra)
Rationale: The correct answer is D because levetiracetam does not
utilize or induce the hepatic Cytochrome P450 (CYP450) enzyme
system, meaning it does not alter the metabolism or efficacy of oral
contraceptive pills. Option A and B are incorrect because
carbamazepine and phenytoin are potent CYP450 enzyme inducers
that significantly accelerate the clearance of estrogen and progestin,
causing OCP failure. Option C is incorrect because topiramate can
induce CYP3A4 at higher therapeutic doses (typically >200 mg/day),
which also lowers oral contraceptive concentrations.
Q3: A 72-year-old female with post-herpetic neuralgia presents with
a pain score of 8/10. Her past medical history is significant for Stage 3
chronic kidney disease (eGFR 42 mL/min/1.73m²) and a history of
falls due to orthostatic hypotension. According to advanced practice
prescriptive guidelines, which medication choice and dosing strategy
represent the safest decision tree path?
A) Initiate gabapentin (Neurontin) at 300 mg three times daily.
B) Initiate pregabalin (Lyrica) at a reduced initial dose of 25 mg daily
at bedtime with slow titration.
C) Initiate amitriptyline (Elavil) 25 mg daily at bedtime.
D) Prescribe duloxetine (Cymbalta) 60 mg daily with a high-dose
, 4
loading sequence.
Rationale: The correct answer is B because pregabalin is highly
effective for neuropathic pain but is eliminated entirely unchanged by
the kidneys; therefore, renal impairment requires a major down-
titration of the initial dose to avoid accumulation, excessive sedation,
and worsening fall risks. Option A is incorrect because starting
gabapentin at 900 mg/day in an older adult with compromised GFR is
too aggressive and introduces a high risk of ataxia and somnolence.
Option C is incorrect because amitriptyline is a tricyclic
antidepressant with profound anticholinergic and alpha-blocking
properties, making it highly inappropriate for an older adult with a
history of falls according to the Beers Criteria. Option D is incorrect
because a standard high-dose configuration of duloxetine is
inappropriate without checking tolerance, and it requires careful
monitoring in renal impairment.
Q4: A 45-year-old female with severe rheumatoid arthritis has failed
to achieve remission despite 6 months of optimized methotrexate
monotherapy. The clinical decision tree leads to the addition of a
biological response modifier. Before initiating an anti-TNF alpha agent
such as adalimumab (Humira), which diagnostic screening action is
mandatory?
A) Perform a QuantiFERON-TB Gold test and a hepatitis B virus
panel.
B) Obtain a baseline bone mineral density DXA scan.
C) Assess a 24-hour urine collection for total protein clearance.
D) Order a brain MRI to rule out silent demyelinating plaques.
Rationale: The correct answer is A because anti-TNF therapies
suppress granuloma formation, which can cause the catastrophic
reactivation of latent infections such as tuberculosis or hepatitis B.
Screening is legally mandated prior to initiation. Option B is incorrect
NURS 6521 ADVANCED PHARMACOLOGY NEURO &
MUSCULOSKELETAL DECISION TREE FULL PACKAGE QUESTIONS
ANSWERS AND RATIONALES 2026-27 LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
INTRODUCTION
The NURS 6521: Advanced Pharmacology examination evaluates graduate-level nursing candidates
on their mastery of advanced prescriptive logic, pharmacokinetics, and pharmacodynamics across
the lifespan. This specialized module focuses on the Neurological and Musculoskeletal Decision
Tree, assessing a clinician's ability to translate complex pathophysiological pathways into safe,
targeted drug therapy. Prescribing for neuro-musculoskeletal conditions requires a deep
understanding of neurotransmitter dynamics, drug-metabolizing enzyme pathways, blood-brain
barrier penetration variables, and national safety alerts like the Beers Criteria.
Advanced practice nurses must navigate challenging clinical situations, such as managing dopamine
agonist selection in Parkinson's disease, adjusting antiepileptic drug (AED) regimens based on hepatic
autoinduction, mitigating the toxicities of biologic response modifiers in rheumatoid arthritis, and
evaluating the safety profiles of muscle relaxants in older adults. This comprehensive question bank
provides scenario-based, application-level questions that mirror the construction of the actual exam.
By engaging with these high-fidelity items and their detailed rationales, candidates can eliminate
knowledge deficits and develop the diagnostic reasoning needed to pass the NURS 6521 examination
on their first attempt.
CORE DOMAINS TESTED
• Domain 1: Neurodegenerative Disorders & Dopaminergic Pathways – Prescriptive decision
trees for Parkinson's disease, Alzheimer's dementia, and corresponding drug-drug
interactions.
• Domain 2: Advanced Seizure Management & Antiepileptic Pharmacokinetics – AED
selection based on seizure classification, enzyme-inducing characteristics, and narrow
therapeutic index monitoring.
• Domain 3: Neuropathic Pain & Chronic Pain Pharmacotherapeutics – Clinical selection of
calcium channel alpha-2-delta ligands, SNRIs, and safety profiles for chronic neuropathic
states.
• Domain 4: Inflammatory and Autoimmune Musculoskeletal Disorders – Biological and non-
biological DMARD decision trees, uric acid mitigation strategies for gout, and glucocorticoid
titration hazards.
• Domain 5: Muscle Spasticity and Skeletal Muscle Relaxants – Differentiation between
centrally acting antispasmodics and peripherally acting muscle relaxants, highlighting
geriatric toxicities.
,2
Q1: A 67-year-old male with a 5-year history of Parkinson's disease
presents with worsening bradykinesia and rigid tremors. He has been
taking carbidopa-levodopa 25/100 mg three times daily. The nurse
practitioner notes that his symptoms return approximately 45
minutes before his next scheduled dose. Which of the following is the
most appropriate next pharmacotherapeutic step in this patient's
decision tree?
A) Discontinue carbidopa-levodopa and initiate high-dose
pramipexole monotherapy.
B) Add entacapone (Comtan) to the current carbidopa-levodopa
regimen.
C) Add benztropine (Cogentin) to manage the motor fluctuations.
D) Increase the carbidopa-levodopa dose and add immediate-release
diphenhydramine.
Rationale: The correct answer is B because the patient is experiencing
the classic "wearing-off" phenomenon associated with long-term
levodopa therapy. Entacapone is a selective, reversible catechol-O-
methyltransferase (COMT) inhibitor that extends the plasma half-life
of levodopa by blocking its peripheral metabolism, thereby increasing
its availability to the brain and mitigating wearing-off intervals.
Option A is incorrect because abruptly discontinuing carbidopa-
levodopa can precipitate neuroleptic malignant syndrome-like
withdrawal and pramipexole monotherapy is insufficient for
advanced disease. Option C is incorrect because benztropine is an
anticholinergic that poses severe central nervous system risks in an
older adult, including confusion and urinary retention under the Beers
Criteria. Option D is incorrect because adding diphenhydramine
increases the anticholinergic burden without addressing the specific
pharmacokinetic mechanism of levodopa clearance.
,3
Q2: A 28-year-old female patient with a new diagnosis of focal
impaired awareness seizures is being started on antiepileptic
monotherapy. She emphasizes that she uses an oral contraceptive pill
(OCP) for birth control and wants to avoid any interactions that could
result in unintended pregnancy. Which of the following antiepileptic
medications is the most appropriate choice for this patient?
A) Carbamazepine (Tegretol)
B) Phenytoin (Dilantin)
C) Topiramate (Topamax)
D) Levetiracetam (Keppra)
Rationale: The correct answer is D because levetiracetam does not
utilize or induce the hepatic Cytochrome P450 (CYP450) enzyme
system, meaning it does not alter the metabolism or efficacy of oral
contraceptive pills. Option A and B are incorrect because
carbamazepine and phenytoin are potent CYP450 enzyme inducers
that significantly accelerate the clearance of estrogen and progestin,
causing OCP failure. Option C is incorrect because topiramate can
induce CYP3A4 at higher therapeutic doses (typically >200 mg/day),
which also lowers oral contraceptive concentrations.
Q3: A 72-year-old female with post-herpetic neuralgia presents with
a pain score of 8/10. Her past medical history is significant for Stage 3
chronic kidney disease (eGFR 42 mL/min/1.73m²) and a history of
falls due to orthostatic hypotension. According to advanced practice
prescriptive guidelines, which medication choice and dosing strategy
represent the safest decision tree path?
A) Initiate gabapentin (Neurontin) at 300 mg three times daily.
B) Initiate pregabalin (Lyrica) at a reduced initial dose of 25 mg daily
at bedtime with slow titration.
C) Initiate amitriptyline (Elavil) 25 mg daily at bedtime.
D) Prescribe duloxetine (Cymbalta) 60 mg daily with a high-dose
, 4
loading sequence.
Rationale: The correct answer is B because pregabalin is highly
effective for neuropathic pain but is eliminated entirely unchanged by
the kidneys; therefore, renal impairment requires a major down-
titration of the initial dose to avoid accumulation, excessive sedation,
and worsening fall risks. Option A is incorrect because starting
gabapentin at 900 mg/day in an older adult with compromised GFR is
too aggressive and introduces a high risk of ataxia and somnolence.
Option C is incorrect because amitriptyline is a tricyclic
antidepressant with profound anticholinergic and alpha-blocking
properties, making it highly inappropriate for an older adult with a
history of falls according to the Beers Criteria. Option D is incorrect
because a standard high-dose configuration of duloxetine is
inappropriate without checking tolerance, and it requires careful
monitoring in renal impairment.
Q4: A 45-year-old female with severe rheumatoid arthritis has failed
to achieve remission despite 6 months of optimized methotrexate
monotherapy. The clinical decision tree leads to the addition of a
biological response modifier. Before initiating an anti-TNF alpha agent
such as adalimumab (Humira), which diagnostic screening action is
mandatory?
A) Perform a QuantiFERON-TB Gold test and a hepatitis B virus
panel.
B) Obtain a baseline bone mineral density DXA scan.
C) Assess a 24-hour urine collection for total protein clearance.
D) Order a brain MRI to rule out silent demyelinating plaques.
Rationale: The correct answer is A because anti-TNF therapies
suppress granuloma formation, which can cause the catastrophic
reactivation of latent infections such as tuberculosis or hepatitis B.
Screening is legally mandated prior to initiation. Option B is incorrect
